These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32185717)

  • 1. Lysosome as the Black Hole for Checkpoint Molecules.
    Wang H; Han X; Xu J
    Adv Exp Med Biol; 2020; 1248():325-346. PubMed ID: 32185717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
    Gao A; Sun Y; Peng G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint blockade opens a new way to cancer immunotherapy.
    Sadreddini S; Baradaran B; Aghebati-Maleki A; Sadreddini S; Shanehbandi D; Fotouhi A; Aghebati-Maleki L
    J Cell Physiol; 2019 Jun; 234(6):8541-8549. PubMed ID: 30511409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical Functions of the Lysosome in Cancer Biology.
    Davidson SM; Vander Heiden MG
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():481-507. PubMed ID: 27732799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction.
    Liu J; Xu J
    Adv Exp Med Biol; 2020; 1248():1-6. PubMed ID: 32185704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Destination 'lysosome': a target organelle for tumour cell killing?
    Castino R; Démoz M; Isidoro C
    J Mol Recognit; 2003; 16(5):337-48. PubMed ID: 14523947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysosomes as mediators of drug resistance in cancer.
    Zhitomirsky B; Assaraf YG
    Drug Resist Updat; 2016 Jan; 24():23-33. PubMed ID: 26830313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy.
    Zhao X; Subramanian S
    Pharmacol Ther; 2018 Jan; 181():76-84. PubMed ID: 28720430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.
    Patel SA; Minn AJ
    Immunity; 2018 Mar; 48(3):417-433. PubMed ID: 29562193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Lysosome for Cancer Therapy.
    Towers CG; Thorburn A
    Cancer Discov; 2017 Nov; 7(11):1218-1220. PubMed ID: 29097619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell biology in China: Focusing on the lysosome.
    Yang C; Wang X
    Traffic; 2017 Jun; 18(6):348-357. PubMed ID: 28371106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for anti-OX40 cancer immunotherapy.
    Aspeslagh S; Postel-Vinay S; Rusakiewicz S; Soria JC; Zitvogel L; Marabelle A
    Eur J Cancer; 2016 Jan; 52():50-66. PubMed ID: 26645943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysosome Membrane Permeabilization and Disruption of the Molecular Target of Rapamycin (mTOR)-Lysosome Interaction Are Associated with the Inhibition of Lung Cancer Cell Proliferation by a Chloroquinoline Analog.
    Sironi J; Aranda E; Nordstrøm LU; Schwartz EL
    Mol Pharmacol; 2019 Jan; 95(1):127-138. PubMed ID: 30409790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Not All Immune Checkpoints Are Created Equal.
    De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
    Front Immunol; 2018; 9():1909. PubMed ID: 30233564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming Therapeutic Resistance by Targeting Cancer Inflammation.
    Beatty GL
    Am Soc Clin Oncol Educ Book; 2016; 35():e168-73. PubMed ID: 27249720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms and functions of lysosome positioning.
    Pu J; Guardia CM; Keren-Kaplan T; Bonifacino JS
    J Cell Sci; 2016 Dec; 129(23):4329-4339. PubMed ID: 27799357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysosome trafficking and signaling in health and neurodegenerative diseases.
    Lie PPY; Nixon RA
    Neurobiol Dis; 2019 Feb; 122():94-105. PubMed ID: 29859318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The application of nanotechnology in immune checkpoint blockade for cancer treatment.
    Deng H; Zhang Z
    J Control Release; 2018 Nov; 290():28-45. PubMed ID: 30287266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.